Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Hungary
Management Report
Published: January 2010
Pages: 48
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Hungary is a landlocked country in central Europe. The population stands at 9.9 million in 2010, of whom 16.0% are aged 65 or over. Hungary is one of the ten countries that joined the EU in May 2004. EU Directives have been transposed into national legislation; Directive 2004/27/EC was implemented in November 2005.
Funding for healthcare in Hungary is managed by the National Health Insurance Fund Administration (NHIFA), which runs the only health insurance fund in the country. In February 2008, a new bill on health insurance was signed into law, which enabled private companies to buy shares in 22 new health funds. However, the legislation was repealed in May 2008 and the health funds are to be phased out.
Around 65% of the pharmaceutical market is supplied by imports. France, Germany and Switzerland were the leading suppliers in 2007, accounting for over 55% of imports. The value of imports has increased every year since 2001.
Sources of funding for pharmaceuticals include the pharmaceutical industry itself as drug companies have been forced to contribute part of their turnover to the Health Insurance Fund, in order to cover government overspending. The Pharma Economic Act, which came into force in January 2007, successfully prevented the drugs budget from running into deficit for the first time in over a decade. However, manufacturers have reported loss of profits since the enforcement of the Act.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel
Funding for healthcare in Hungary is managed by the National Health Insurance Fund Administration (NHIFA), which runs the only health insurance fund in the country. In February 2008, a new bill on health insurance was signed into law, which enabled private companies to buy shares in 22 new health funds. However, the legislation was repealed in May 2008 and the health funds are to be phased out.
Around 65% of the pharmaceutical market is supplied by imports. France, Germany and Switzerland were the leading suppliers in 2007, accounting for over 55% of imports. The value of imports has increased every year since 2001.
Sources of funding for pharmaceuticals include the pharmaceutical industry itself as drug companies have been forced to contribute part of their turnover to the Health Insurance Fund, in order to cover government overspending. The Pharma Economic Act, which came into force in January 2007, successfully prevented the drugs budget from running into deficit for the first time in over a decade. However, manufacturers have reported loss of profits since the enforcement of the Act.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel